Medical/Pharmaceuticals
ABL Bio Receives IND Approval for Phase 1 Clinical Trial of ABL501, an anti-LAG-3/PD-L1 Bispecific Antibody
* South Korea's MFDS clears IND application for a Phase 1 study evaluating the safety and preliminary efficacy of ABL501 as a monotherapy for solid tumor treatment * ABL's third IND this year for bispecific antibody therapeutics SEONGNAM, South Korea, Aug. 4, 2021 /PRNewswire/ -- ABL Bio, Inc...
Novavax and European Commission Finalize Advance Purchase Agreement for up to 200 million doses of COVID-19 Vaccine
GAITHERSBURG, Md., Aug. 4, 2021 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, today announced that it has reached an agreement with the European Commission (EC) for the purchase of up to 200 million doses...
Alterity Therapeutics Announces New US Patent to Expand its Portfolio of Compounds for Neurodegenerative Diseases including Alzheimer's and Parkinson's
MELBOURNE, Australia, Aug. 4, 2021 /PRNewswire/ -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative conditions, today announced the United States Patent and Trademark Of...
New Global Study Reveals Post-Pandemic Consumer Behaviours, Expectations and Concerns
Enduring appeal of in-store shopping, and continued fears about data privacy among surprising findings in "Future of Commerce |The Why Behind the Buy" LONDON, Aug. 4, 2021 /PRNewswire/ -- As the marketing industry worldwide continues its efforts to both map and navigate the post-pandemic commerce...
MitraClip implant at Apollo Hospitals saves 41-year-old farmer who waited 91 days for heart transplant
"1 out of 5 patients may get off the heart transplant list if they have access to this therapy" - says Dr. Sai Satish CHENNAI, India, Aug. 4, 2021 /PRNewswire/ -- Apollo Hospitals, Asia's foremost and most trusted healthcare group, today announced a successful MitraClip implant on a 41-year-old ...
Insilico Medicine Announces the Preclinical Candidate for Kidney Fibrosis Discovered Using End-to-End Artificial Intelligence Engine
HONG KONG, Aug. 4, 2021 /PRNewswire/ -- Insilico Medicine, a global company specializing in the applications of the next-generation machine learning technologies for drug discovery and development, announced today that its AI-powered drug discovery platform had delivered the preclinical candidate...
Columbia Clinic signed a cooperation agreement with Boehringer Ingelheim
SHANGHAI, Aug. 4, 2021 /PRNewswire/ -- On August 3rd, 2021, Columbia China, signed a cooperation agreement with Consanas Rehabilitation, brand of Boehringer Ingelheim. The agreement will allow both parties to complement each other's medical resources and to carry out in-depth collaboration on tal...
Clarivate Acquires Bioinfogate, Reinforcing Position as Premier Provider of End-to-End Research Intelligence Solutions for Life Sciences
LONDON, Aug. 4, 2021 /PRNewswire/ -- Clarivate Plc (NYSE:CLVT), a global leader in providing trusted information and insights to accelerate the pace of innovation, today announced that it has acquired Bioinfogate, a leading provider of analytics solutions in the life sciences and producer of the ...
OPEN Health acquires Spirit
LONDON, Aug. 4, 2021 /PRNewswire/ -- OPEN Health has today announced the acquisition of North West UK-based medical communications agency Spirit. Integrating the Spirit business with the OPEN Health Group further strengthens our ability to offer our global Medical Affairs audiences a broad range ...
NaviFUS begins FUS combined with radiotherapy clinical trial for the treatment of terminal primary brain tumors
TAIPEI, Aug. 4, 2021 /PRNewswire/ -- NaviFUS' focused ultrasound (FUS) therapy system (NaviFUS®) was recently approved for use in a new clinical trial by the Taiwan Food and Drug Administration (TFDA). It will be initiated shortly at Linkou Chang Gung Memorial Hospital. The trial will investigate...
TIENS Group will Become a Global Participant in the Future Massive Health Industry
TIANJIN, China, Aug. 4, 2021 /PRNewswire/ -- As announced proudly by TIENS Group's Chairman Li Jinyuan in theHealth Industry Development Forum of the Belt and Road in the Post-pandemic Era held in Tianjin, China, TIENS Group is poised to become one of main global participants in the future massiv...
Lumosa Therapeutics Announces Positive Results from LT3001 Phase 2a Clinical Trial in Acute Ischemic Stroke
* LT3001 met primary safety endpoint. No symptomatic intracranial hemorrhage occurred. * LT3001 showed pronounced neurological improvement in the majority of patients with baseline NIHSS≥6 treated with LT3001. * These data suggest that LT3001 has the potential to provide significant clinica...
Varigard Technologies Proven to Prevent the Tactile Spread of SARS-CoV-2, B.1.617.2 - DELTA Variant
Varigard's protective Hand Sanitizing lotion prevents the tactical spread of SARS-CoV-2, B.1.617.2 for two hours and for over 20 hours with its organic Surface Spray FOLEY, Ala., Aug. 3, 2021 /PRNewswire/ -- Varigard and Synergy Laboratories have announced the test results of an advanced hand sa...
Yuyu Pharma Signs Exclusive Distribution Agreement with Novartis Korea for Domestic Distribution Rights in Korea for Lamisil®, Lescol® XL and Tegretol®
SEOUL, South Korea, Aug. 3, 2021 /PRNewswire/ -- Yuyu Pharma, a pharmaceutical company based in Korea, and Novartis Korea announced today that the companies have entered into an agreement in which Yuyu will have exclusive distribution rights for the following prescription medicines in Korea: Lami...
Pulnovo Medical, a pioneer medical device company, specializing in the treatment of pulmonary artery hypertension, recently raised millions of dollars through OrbiMed Healthcare Fund Management, Cenova Capital, Lilly Asia Ventures(LAV), and GaoRong Capital
NANJING, China, Aug. 3, 2021 /PRNewswire/ -- Pulnovo Medical, a pioneer medical device company, specializing in the treatment of pulmonary artery hypertension, recently raised millions of dollars through OrbiMed, Cenova, Lilly Asia Ventures (LAV), and GaoRong Capital. Funds raised in this round w...
CartiHeal Announces Pivotal Study Results Demonstrate Agili-C™ Superiority to Microfracture and Debridement for the Treatment of Cartilage and Osteochondral Defects
According to a Two-Year Randomized and Controlled Multinational IDE Study KFAR SABA, Israel, Aug. 3, 2021 /PRNewswire/ -- CartiHeal Ltd, developer of Agili-C™, a proprietary implant for the treatment of cartilage lesions in arthritic and non-arthritic joints, which was granted Breakthrough Device...
111, Inc. Enters into Strategic Cooperation Agreement with Zelgen to Develop a New Management Platform for Liver Cancer Patients in China
SHANGHAI, Aug. 3, 2021 /PRNewswire/ – 111, Inc. ("111" or the "Company") (NASDAQ: YI), a leading tech-enabled healthcare platform company committed to digitally connecting patients with medicine and healthcare services inChina, today announced a strategic cooperation agreement with Suzhou Zelgen ...
Clinical Trial Affirms CoviDTH Diagnostic Approach to screen for T cell-mediated immune response to SARS-CoV-2 is safe and effective in humans
Yvelise Barrios, MD, PhD, Immunologist and leading expert in the clinical use of delayed type hypersensitivity ("DTH"), the mechanism behindCoviDTH, joins BioVaxys as scientific adviser VANCOUVER, BC and SAN CRISTÓBAL DE LA LAGUNA, Spain, Aug. 3, 2021 /PRNewswire/ -- BioVaxys Technology Corp. (C...
TCM Lianhua Qingwen shows stable in vitro antiviral effect on the Delta variant: Expert
GUANGZHOU, China, Aug. 3, 2021 /PRNewswire/ -- The latest research findings from the team of Professor Yang Zifeng from the State Key Laboratory of Respiratory Disease inGuangzhou, China, have showed that Chinese medicine Lianhua Qingwen has an effective inhibitory action on the Delta variant of ...
Nanoform and Boehringer Ingelheim execute master services agreement
HELSINKI, Aug. 3, 2021 /PRNewswire/ -- Nanoform, an innovative nanoparticle medicine enabling company, announces that Proof of Concept studies may now be performed for Boehringer Ingelheim to assess the added value Nanoform's award-winning CESS® technology can deliver to its drug development proj...
Week's Top Stories
Most Reposted
Edufrienz 99: One of Asia's First Digital Platform Advancing Character Education for Future-Ready, Compassionate Children
[Picked up by 315 media titles]
2026-01-23 11:03UOB prices AUD2 billion in five-year senior unsecured notes
[Picked up by 307 media titles]
2026-01-23 09:00AVPN's AI Opportunity Fund Expands Regional Efforts to Build AI Skilling Infrastructure for a Future-Ready Workforce Across Asia-Pacific
[Picked up by 300 media titles]
2026-01-21 12:39Government of Telangana and Blaize Sign MoU at Davos to Launch Telangana AI Innovation Hub and Advance Applied AI Initiatives
[Picked up by 297 media titles]
2026-01-22 15:16Klook's study of 374,000 reviews finds that lesser-known cities create deeper emotional connection with travelers
[Picked up by 280 media titles]
2026-01-20 15:40